Phase I ABL001X2101: Novel BCR-ABL1 Inhibitor ABL001 Safe With Promising Activity in TKI-Resistant Chronic-Phase CML

December 3-6, 2016; San Diego, California
ABL001 showed early indications of clinical activity in chronic-phase CML patients both with and without TKI resistance mutations.
Format: Microsoft PowerPoint (.ppt)
File Size: 400 KB
Released: December 7, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

Read expert answers to clinician questions on optimizing the care of patients with CLL in today’s practice, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Susan M. O'Brien, MD John Pagel Headshot John Pagel, MD, PhD Released: January 15, 2021

Expert answers to clinician questions on current challenges in managing patients with myelodysplastic syndromes (MDS), from Clinical Care Options (CCO)

Guillermo Garcia-Manero, MD Rami S. Komrokji, MD Jamile Shammo, MD, FASCP, FACP Released: January 11, 2021

Expert commentary by Lydia Scarfò, MD, providing a European perspective on key studies in CLL and lymphomas from ASH 2020 as reported by Clinical Care Options (CCO)

Lydia Scarfò, MD Released: January 4, 2021

Gain key clinical insights fast, with this short slideset from CCO on optimal management of patients with MM

Brian G.M. Durie, MD Shaji Kumar, MD Thomas G. Martin, MD Philippe Moreau, MD S. Vincent Rajkumar, MD Jesús F. San-Miguel, MD, PhD Released: December 30, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue